| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.095 | 0.08 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.08 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.08 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.09 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.1 |